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OBJECTIVE: To evaluate the health care costs of a physician-
pharmacist collaborative care (PPCC) over usual care (UC) for
patients at moderate (MR) or high risk (HR) of coronary heart
disease with dyslipidemia. Trained community pharmacists
provided advance care including monitoring of laboratory tests
and lipid-lowering medication dosage adjustments. METHODS:
Annual direct health care costs and incremental costs were esti-
mated from an interim analysis of a 3-year cluster randomised
controlled trial (TEAM study) evaluating the efﬁcacy of a PPCC
versus UC for patients on a statin but not at lipid targets. The
mean annual costs of pharmacists’ follow-up (pharmacists’ train-
ing, pharmacist visits, laboratory tests), physicians’ follow-up
(physician visits, laboratory tests), lipid-lowering treatment
(medication, pharmacists’ fee), and total cost (pharmacists’
follow-up, physicians’ follow-up, lipid-lowering treatment) were
compared between groups by t-tests. RESULTS: Geographical
clusters of general practitioners (GP) and pharmacists were ran-
domised to PPCC (GP = 41; pharmacists = 58) or UC (GP = 36;
pharmacists = 46) and followed 167 patients (PPCC = 67;
UC = 100). Costs for the pharmacists’ follow-up per patient were
CND$390.80 and CND$410.53 for MR and HR, respectively,
including CND$320.67 per patient for the pharmacists’ training.
Total costs per PPCC patient were signiﬁcantly higher than for
UC patient (MR: 9CND$25.84 vs. CND$529.39; HR:
CND$1065.39 vs. CND$591.48). Incremental costs per patient
for the physicians’ follow-up were: CND$33.38 (p = 0.004)
for MR and CND$16.17 (p = 0.07) for HR, and for the
lipid-lowering treatment, CND$39.04 (p = 0.6) for MR and
CND$79.69 (p = 0.06) for HR. Incremental total costs per
patient were CND$396.45 (p < 0.0001) for MR and,
CND$473.91 (p < 0.0001) for HR. Assuming an incremental
efﬁcacy of 10% LDL reduction between groups, ICERs per
patient (95% CI) would be CND$39.65 (2CND$1.35 to
CND$57.94) for MR and CND$47.39 (CND$38.54 to
CND$56.24) for HR per % LDL reduction. CONCLUSION:
Community pharmacists can provide advance care to patients
with dyslipidemia at a reasonable cost and contribute to reduce
the GP workload.
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OBJECTIVE: After several years of use, the cost-effectiveness
question of drug-eluting stents (DES) has not been answered
satisfactorily due to a limited time horizon in previous analyses.
Using four year follow-up clinical data from a large meta-
analysis we examined the cost-effectiveness of Cypher and Taxus
stents compared to bare-metal stents with a decision analytic
cost-utility model from a Medicare payer perspective.
METHODS: We developed a ﬁve state Markov cost-utility deci-
sion analytic model. The model included the events MI, CABG
and the need for a repeated percutaneous coronary intervention.
Transition probabilities were directly extracted from the meta-
analysis. Quality of life data was derived from the ARTS trial.
Costs for the resource use (including stenting with DES and
BMS) were obtained from Medicare diagnosis related groups for
ten leading cardiology hospitals and a random sample of ten
United States hospitals offering stenting procedures. All costs are
in USD$ of the ﬁnancial year 2007. Probabilistic sensitivity
analysis was performed with 10,000 Monte Carlo simulations.
RESULTS: Cypher stents are slightly more effective than bare
metal stents with an incremental effect of 0.001 QALYs (95% CI
-0.042 to 0.012 QALYs), while the Taxus stents provide -0.004
incremental QALYs (95% CI -0.064 to 0.012). DES are more
costly than BMS. At a willingness to pay of $100,000/QALY, the
incremental net monetary beneﬁt (INMB) for Cypher stents is
$-940 and $-1612 for Taxus stents, respecively, for the leading
hospitals. Using the random sample of hospitals Cypher and
Taxus stents yield an INMB of $-1146 and $-1751, respectively.
The probability that DES are cost-effective ranges from 34% for
Taxus stents in the random sample to 43% for Cypher stents in
the leading hospitals. CONCLUSION: From a Medicare per-
spective, the use of drug-eluting as compared to bare metal stents
is not cost-effective when implanted in unselected patients with
symptomatic ischemic coronary artery disease.
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OBJECTIVE: To determine the cost-utility of aliskiren in com-
bination or monotherapy vs. usual care for patients with mild to
moderate hypertension from the Canadian health care system
perspective. METHODS: A Markov model was programmed to
simulate patient ﬂow between 17 health states (including death),
different treatment lines and allowing for non-persistence. Car-
diovascular disease (CVD) related outcomes were projected for
over 40 years from systolic blood pressure (SBP) reductions
observed in several randomized trials using risk equations from
landmark studies, including the Framingham Heart Study.
Patients were at low risk of CVD, based on their demographic
and clinical history at baseline. The following comparisons
were analyzed: aliskiren + thiazide-diuretic vs. ACEI + thiazide-
diuretic, ARB + thiazide-diuretic, and CCB + thiazide-diuretic,
aliskiren + CCB vs. thiazide-diuretic + CCB, and aliskiren vs.
ARB. Direct costs for health states and events were taken from
published literature. Weighted average unit prices were obtained
for each antihypertensive drug class. All costs are in 2007 CAD.
The primary outcome was incremental cost per additional
quality-adjusted life-year QALY. Additional outcomes included
life expectancy and number of CVD-related deaths. RESULTS:
Aliskiren + thiazide-diuretic was shown to be dominant vs.
CCB + thiazide-diuretic, cost-effective in monotherapy vs. ARB
($1011/QALY) and cost-effective when in combination therapy
with CCB vs. thiazide-diuretic + CCB ($29,813/QALY). More
variability occurred when comparing aliskiren + thiazide-diuretic
to ARB + thiazide-diuretic (ranging from dominance to being
dominated). Based on pooled data of aliskiren vs. ARBs showing
similar SBP-lowering effect, the cost impact of aliskiren is
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